Form 4: Abbott Laboratories Director Receives Stock Award

Director Sally E. Blount was granted 2,286 restricted stock units under the Abbott Laboratories 2017 Incentive Stock Program.

Summary

• Director Sally E. Blount acquired 2,286 restricted stock units (RSUs) on April 24, 2026.
• The award was granted under the Abbott Laboratories 2017 Incentive Stock Program.
• The RSUs will be settled in common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.
• Following this transaction, the director's total beneficial ownership is 36,344 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial health.

Positives

• The grant of equity aligns the director's interests with those of long-term shareholders.

Negatives

• None identified.

Risks

• The value of the equity award is subject to future fluctuations in Abbott Laboratories' share price.

Future Outlook

The RSUs are deferred until the director's separation from service, death, or a change in control, indicating a long-term retention incentive.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the healthcare and pharmaceutical sectors to ensure alignment with shareholder interests.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices at large-cap companies like Pfizer, Merck, and Johnson & Johnson.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation.

Next Steps

• The director will hold the RSUs until the occurrence of a triggering event such as separation from service.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation